Aleve Challenge, New Study Catch Up To Advil 'Works Longer' Claim In NAD Review
Executive Summary
Although 1993 studies to make Aleve available OTC didn't support claiming the naproxen oral analgesic lasted longer than ibuprofen-containing Advil, 2018 study Bayer submitted for National Advertising Division review shows Advil's efficacy doesn't exceed Aleve's. Report also says while Pfizer criticized inpatient methodology of Bayer's study, inpatient is industry standard method for pain medication trials.
You may also be interested in...
Bayer's Aleve 'Proven Better' Than Tylenol Claims Fail In J&J Challenge At NAD
Bayer appeals to National Advertising Review Board over NAD’s finding the firm didn't support claims its Aleve OTC provides superior pain-relief to J&J’s Tylenol. It says NAD misunderstands scientific data and it will argue pain studies it submitted were methodologically sound and pain-relief statements were not overly broad.
Pfizer Consumer Health True To Form Pending Move To JV With GSK
Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.
Aleve data vs. Advil shows "trend" toward longer action, court says in rejecting AHP suit.
ALEVE CLINICAL DATA VS. ADVIL SHOWS "TREND" TOWARD LONGER ACTION, U.S. District Court Judge Nicholas Politan said Dec. 27 in deny-ing American Home Products' request for a preliminary injunction against Procter-Syntex. Politan stated that "it is patent" from evaluating three studies comparing the pain relief duration of naproxen sodium and ibuprofen with placebo over a 12-hour period that the "consistent trends of all three studies strongly suggest that naproxen sodium, that is, Aleve, has a longer duration and is more efficacious at the later hours (i.e., hours 8 through 12) than Advil."